SNP Consortium's Next Focus Could Be Drug Safety, Bristol Exec Suggests
Executive Summary
The pharmaceutical industry SNP consortium's next focus should be on data that could help minimize side effects, Bristol-Myers Squibb Senior VP-Early Discovery & Applied Technology Elliot Sigal, MD/PhD, suggested.